Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors | Zendy

Hongtao Xiao | Zendy; Zhi | Zendy; Rong-sheng | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors

Author(s) -

Hongtao Xiao,

Zhi,

Rong-sheng

Publication year - 2012

Publication title -

drug design development and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.964

H-Index - 64

ISSN - 1177-8881

DOI - 10.2147/dddt.s36555

Subject(s) - copd , medicine , muscarinic acetylcholine receptor , receptor , disease , intensive care medicine , pharmacology , anticholinergic

The aim of this review was to evaluate and summarize the available scientific information on penehyclidine hydrochloride (PHC) for the treatment of chronic obstructive pulmonary disease (COPD) as a result of its ability to attenuate Toll-like receptors. Penehyclidine hydrochloride is an anticholinergic drug manufactured in China, with both antimuscarinic and antinicotinic activity. PHC is used widely in the clinic as a reversal agent in cases of organic phosphorus poisoning and soman poisoning, but also may also have an important role as a bronchodilator in the treatment of obstructive airway disease, including asthma and, in particular, COPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research